World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
147
Citations
107338
World Ranking
1259
National Ranking
731

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Roy S. Herbst is affiliated with Yale University in the United States. Their work primarily falls within the field of Medicine, with a focus on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The main research topics covering their work include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Radiomics and Machine Learning in Medical Imaging

Recent publications by Roy S. Herbst include:

  • "Longitudinal analyses reveal immunological misfiring in severe COVID-19" (2020, Nature)
  • "Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer" (2020, New England Journal of Medicine)
  • "Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC" (2020, New England Journal of Medicine)
  • "Toward personalized treatment approaches for non-small-cell lung cancer" (2021, Nature Medicine)
  • "Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial" (2020, The Lancet Oncology)

Frequent co-authors collaborating with Roy S. Herbst include:

  • Mary W. Redman
  • Karen Kelly
  • Filippo de Marinis
  • Margarita Majem
  • Kurt A. Schalper

They have contributed extensively to leading publication venues such as:

  • Journal of Clinical Oncology (42 publications)
  • Journal of Thoracic Oncology (27 publications)
  • Annals of Oncology (14 publications)
  • Clinical Cancer Research (11 publications)
  • Cancer Research (11 publications)

Roy S. Herbst has also authored works in the book domain, including a publication titled Lung Cancer (2021) released by Springer International Publishing.

Recognition for their contributions includes their membership in the Association of American Physicians.

Best Publications

  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

    Roy S. Herbst;Paul Baas;Dong Wan Kim;Enriqueta Felip

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • The biology and management of non-small cell lung cancer

    Roy S. Herbst;Daniel Morgensztern;Chris Boshoff;Chris Boshoff

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Molecular origins of cancer: Lung cancer

    Roy S. Herbst;John V. Heymach;Scott M. Lippman;Scott M. Lippman

  • Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

    Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

    David A. Eberhard;Bruce E. Johnson;Lukas C. Amler;Audrey D. Goddard

  • Longitudinal analyses reveal immunological misfiring in severe COVID-19.

    Carolina Lucas;Patrick Wong;Jon Klein;Tiago B R Castro

  • Review of epidermal growth factor receptor biology.

    Roy S Herbst

  • TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

    Roy S. Herbst;Diane Prager;Robert Hermann;Lou Fehrenbacher

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

    Yi-Long Wu;Masahiro Tsuboi;Jie He;Thomas John

  • An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

    Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny

  • Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    Roy S Herbst;Giuseppe Giaccone;Filippo de Marinis;Niels Reinmuth

  • The BATTLE Trial: Personalizing Therapy for Lung Cancer

    Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee

  • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

    Sarah B Goldberg;Scott N Gettinger;Amit Mahajan;Anne C Chiang

  • Programmed death ligand-1 expression in non-small cell lung cancer.

    Vamsidhar Velcheti;Kurt A Schalper;Daniel E Carvajal;Valsamo K Anagnostou

  • Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

    Daphne W. Bell;Thomas J. Lynch;Sara M. Haserlat;Patricia L. Harris

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Diane Prager

Frequent Co-Authors

Vassiliki A. Papadimitrakopoulou
Vassiliki A. Papadimitrakopoulou The University of Texas MD Anderson Cancer Center
David R. Gandara
David R. Gandara University of California, Davis
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Kurt A. Schalper
Kurt A. Schalper Yale University
Waun Ki Hong
Waun Ki Hong The University of Texas MD Anderson Cancer Center
Scott N. Gettinger
Scott N. Gettinger Yale University
David L. Rimm
David L. Rimm Yale University
Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
George R. Blumenschein
George R. Blumenschein The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering studying Medicine in the USA, there are numerous online degrees and alternative healthcare career pathways to explore. Many students pursue advanced or related healthcare degrees online, offering flexibility and affordability.

For example, a Master’s in Healthcare Administration (MHA) is a popular option for those looking to take on leadership roles in hospitals and health organizations. There are many cheapest mha online programs that make this path accessible.

Nursing professionals can strengthen their expertise by enrolling in the cheapest dnp programs, advancing their practice and knowledge.

For those interested in pharmacy, exploring the cheapest online pharmacy school options can lead to rewarding roles in clinical or retail pharmacy.

Alternatively, earning credentials such as an RHIT (Registered Health Information Technician) is possible with accredited online rhit degree programs that focus on health data and information management.

Exploring these online degrees can open doors to rewarding careers in healthcare beyond the traditional physician pathway, often at a lower cost and with greater scheduling flexibility.

Best Scientists Citing Roy S. Herbst

Trending Scientists

Recently Published Articles